Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Spectrum To Acquire Allos Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Spectrum To Acquire Allos Therapeutics

Allos entitled to additional payments for Folotyn milestones

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Spectrum Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of Allos Therapeutics for $206 million upfront, plus a Contingent Value Right (CVR) entitling Allos to an additional payment if certain European regulatory and commercialization milestones for Folotyn are met. Folotyn (pralatrexate injection) is a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The drug generated more than $50 million in U.S. sales in 2011.

“For Spectrum, this acquisition adds another diversified source of revenue, accelerates the development of our hematology franchise, and affirms our commitment to becoming a leader in the treatment of lymphoma,” said Rajesh C. Shrotriya, M.D., chairman, chief executive officer and president of Spectrum Pharmaceuticals. “We are well positioned to immediately leverage the combined strengths of the two companies, while expanding the number of cancer patients that can benefit from our products.”

“This transaction represents an excellent strategic and cultural fit that leverages two strong brands in the hematology/oncology market today with potential for future growth,” said Paul L. Berns, president and chief executive officer of Allos Therapeutics. “Spectrum shares our commitment to patients and their healthcare providers, and we believe Folotyn will be a welcomed addition to its commercial product offering and diversified portfolio of development-stage drugs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters